Anthropic is officially pivoting from building "just smart chatbots" to developing autonomous digital scientists. At a private meeting with pharmaceutical executives, the company unveiled Claude Science—a flagship product that goes beyond conversation to execute complex research cycles. Mechanically, it is the successor to Claude Code: while its predecessor writes software, this new AI agent targets computational biology and drug discovery. For Anthropic, this is a strategic maneuver. Instead of competing head-to-head with OpenAI in the general market, Dario Amodei is pushing the company into deep verticalization, where contract values are higher and entry barriers are measured in domain expertise rather than just raw compute power.
The Engine of Autonomous Discovery
The technical promise of Claude Science is the conversion of vague instructions into concrete experimental actions. As noted by Grace Huckins, the model is equipped with tools to handle molecular-level data. It doesn't just summarize PubMed articles; it performs the heavy lifting. Anthropic has already confirmed it is using Claude Science for internal research into treatments for rare diseases. Essentially, we are witnessing an attempt at vertical integration: an AI lab is transforming into a direct competitor to the pharma giants it once viewed merely as API customers.
Claude Science can autonomously perform meaningful scientific work based on brief, high-level instructions.
By automating the "middle layer" of R&D—data processing and computer modeling—Anthropic is targeting the industry’s biggest pain point: operating expenses. However, this path contains a vendor-lock-in trap. If a biotech startup builds its pipeline on Claude’s proprietary logic, the cost of switching to another model becomes prohibitive. Compounding this is the "black box" problem: if an AI makes a breakthrough autonomously, the lack of human-reproducible steps could become an insurmountable hurdle for regulators like the FDA.
Geopolitical Leverage and the Mythos Factor
This aggressive push into the scientific sector coincides suspiciously with a regulatory triumph for Anthropic: U.S. authorities have lifted restrictions on the use of its Mythos and Fable models. This gives the company carte blanche to integrate its most powerful algorithms into the Claude Science ecosystem. Washington appears to have decided that the risk of falling behind in the biotechnology race outweighs concerns regarding the safety of uncontrolled AI models.
The U.S. lifted restrictions on Anthropic’s Mythos and Fable models, clearing their path into the laboratory.
The strategic goal is transparent: to capture the infrastructure of next-generation medicine. While the industry remains cautious, hesitant to trust results without "human fingerprints," Anthropic is forcing the issue. The lifting of restrictions just in time for a presentation to pharma leadership looks like a perfectly choreographed sequence. For a company that desperately needs to prove its multi-billion-dollar valuation converts into actual chemical compounds—and not just slick demo videos—the stakes in this endgame couldn't be higher.